



Press Release



25 June 2024

Aspen announces exclusive licensing agreement with Wooshin Labottach for Lidocaine 700mg medicated plasters

Dublin, Ireland – Aspen Pharma Ireland Limited (“Aspen”), a subsidiary of Aspen Pharmicare Holdings Limited, a JSE-listed global multinational specialty pharmaceutical company, is pleased to announce that it has successfully concluded an exclusive licensing agreement with the Republic of Korea-based Wooshin Labottach Co. LTD, for Lidocaine 700mg medicated plasters, in selected European Union (EU) markets.

Lidocaine 700mg medicated plasters are indicated for the symptomatic relief of neuropathic pain associated with previous herpes zoster infection (post-herpetic neuralgia, PHN) in adults.

Daniel Vella Friggieri, Aspen's Regional CEO for Europe and the Middle East, said, "The addition of Lidocaine 700mg medicated plasters to our portfolio further strengthens Aspen's product range in the European and Middle Eastern territories. This collaboration with Wooshin Labottach highlights Aspen's commitment to broadening our reach and delivering high quality therapeutic solutions to healthcare professionals and patients alike."

Tack Soo Nam, CEO of Wooshin Labottach, commented, "We are very pleased to sign a licensing agreement for Lidocaine 700mg medicated plasters with Aspen, a global multinational specialty pharmaceutical company, and hope that this will serve as an opportunity to expand the reach of our product with Aspen to Europe, MENA and South Africa."

Ends

Issued by: Firas Nabulsi, Aspen Europe & Middle East Head of Business Development and Marketing
Tel: +971 4 363 4932 | FNabulsi@ae.aspenpharma.com

On behalf of: Daniel Vella Friggieri, Aspen Europe & Middle East Regional CEO
Tel: +971 4 363 4925 | dvella@ae.aspenpharma.com

About Aspen

Headquartered in Durban, South Africa, Aspen is a global specialty and branded multinational pharmaceutical company with a presence in both emerging and developed markets. Aspen employs more than 9 100 employees at 65 established offices in over 50 countries and territories.

Aspen focuses on marketing and manufacturing a broad range of post-patent, branded medicines and regional brands covering both hospital and consumer markets. The Group's key business segments are Manufacturing and Commercial Pharmaceuticals comprising injectable products, prescription and OTC medicines.

Aspen improves the health of patients around the world through its high quality, affordable and effective healthcare solutions. The Group operates 23 manufacturing facilities across 15 sites and holds international manufacturing approvals from some of the most stringent global regulatory agencies. The Group's manufacturing capabilities cover a wide variety of product types including steriles, oral solid dose, liquids, semi-solids, biologicals and active pharmaceutical ingredients.

For more information visit www.aspenpharma.com

About Wooshin Labottach

Founded in 1992 and headquartered in Seoul, Korea, Wooshin Labottach is a health and beauty SME specializing in patch and ODF (Orally Disintegrating Film) technology.

With its own R&D and RA (Regulatory Affairs) teams, Wooshin Labottach supplies customers from two manufacturing sites: Wooshin Labottach in Korea and Wooshin LaPache in Slovenia.

The company exports to 70 countries and engages in licensing agreements with pharmaceutical companies, as well as distributing pharma raw materials for the domestic market. Wooshin Labottach prioritizes innovation, quality, and customer value, continually introducing new products in the pharmaceutical and health & beauty sectors.

For more information visit www.wooshinmed.com